title: Intranasal chalcone, Ro 09-0410, as prophylaxis against rhinovirus infection in human volunteers.
abstract: The antirhinovirus agent chalcone Ro 09-0410 was tested in double-blind place-controlled volunteer trials for its protective efficacy against experimental rhinovirus infection. Fifty volunteers received either drug (26 volunteers) or placebo (24 volunteers) both before and after challenge with 20-40 tissue culture infecting dose (TCID50) of human rhinovirus 2 (RV2). There was no evidence that medication significantly reduced the incidence of infection or illness, indeed there was some increase in the nasal secretion produced.
authors.affiliation: MRC Common Cold Unit, Harvard Hospital, Salisbury, Wiltshire, U.K.
authors.forename: W
authors.initials: W
authors.lastname: Al-Nakib
authors.forename: P G
authors.initials: PG
authors.lastname: Higgins
authors.forename: I
authors.initials: I
authors.lastname: Barrow
authors.forename: D A
authors.initials: DA
authors.lastname: Tyrrell
authors.forename: I
authors.initials: I
authors.lastname: Lenox-Smith
authors.forename: H
authors.initials: H
authors.lastname: Ishitsuka
mesh_terms: D000281:Administration, Intranasal; D000998:Antiviral Agents / Q000008:administration & dosage*; D002599:Chalcone / Q000008:administration & dosage* / Q000031:analogs & derivatives; D047188:Chalcones; D002986:Clinical Trials as Topic; D003139:Common Cold / Q000517:prevention & control*; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008297:Male; D011427:Propiophenones / Q000008:administration & dosage*
chemical_list: D000998:Antiviral Agents; D047188:Chalcones; D011427:Propiophenones; D002599:Chalcone; C036425:Ro 09-0410